Skip to main content

Baker Julian's Form 4 filing

BeOne Medicines Ltd. (ONC) · filed Feb 28, 2025

Accession no.
0000950170-25-030318
Filed
Feb 28, 2025, 9:28 PM ET
Trade date
Feb 28, 2025
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market sales total $190.5M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Baker JulianCIK 0001087939Director
Baker FelixCIK 0001087940Director
Baker Bros. Advisors LPCIK 0001263508Director
Baker Brothers Life Sciences LPCIK 0001363364Director
667, L.P.CIK 0001551139Director
Baker Bros. Advisors (GP) LLCCIK 0001580575Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 28, 2025American Depositary SharesSSaleDisposed−60,851$260.00−$15,821,260730,642Indirect
Feb 28, 2025American Depositary SharesSSaleDisposed−671,976$260.00−$174,713,7608,068,411Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

Michael Goller and Ranjeev Krishana, full-time employees of Baker Bros. Advisors LP, are directors of BeiGene, Ltd. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.

Read the full filing on SEC EDGAR (opens in a new tab)